Synerrv Atorvastatin Indications/Uses

Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and triglycerides (TG) and to increase high density lipoprotein (HDL-C) in patients with primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia), combined (mixed) hyperlipidemia (Frederickson Types IIa and IIb), elevated serum TG levels (Frederickson Type IV), and for patients with dysbetalipoproteinemia (Frederickson Type III) who do not respond adequately to diet.
Atorvastatin is also indicated for the reduction of total-C and LDL-C in patients with homozygous familial hypercholesterolemia.
Prevention of Cardiovascular Disease: In adult patients without clinically evident cardiovascular disease (CVD), but with multiple risk factors for coronary heart disease (CHD) such as age, smoking, hypertension, low HDL-C, or a family history of early CHD, Atorvastatin is indicated to: Reduce the risk of myocardial infarction (MI); Reduce the risk o stroke; Reduce the risk for revascularization procedures and angina.
In patients with type 2 diabetes, and without clinically evident CHD, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin is indicated to: Reduce the risk of myocardial infarction; Reduce the risk of stroke.
In patients with clinically evident coronary heart disease, atorvastatin is indicated to: Reduce the risk of non-fatal MI; Reduce the risk of fatal and non-fatal stroke; Reduce the risk for revascularization procedures; Reduce the risk of hospitalization for congestive heart failure (CHF); Reduce the risk of angina.
Pediatric Patients (10-17 years of age): Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥190 mg/dL or LDL-C remains ≥160 mg/dL and: There is a positive family history of premature CVD or two or more other CVD risk factors are present in the pediatric patient.